
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TWEAK CRISPR/Cas9 KO Plasmid (m) | sc-423449 | 20 µg | $397.00 |
Mouse Tnfsf12 encodes TWEAK (TNF-like weak inducer of apoptosis), a type II transmembrane cytokine of the TNF superfamily that can be released as a soluble ligand and signals primarily through the FN14/Tnfrsf12a receptor. TWEAK–FN14 engagement regulates inflammatory gene programs and tissue remodeling by activating canonical and non-canonical NF-κB pathways and modulating MAPK signaling, influencing cell survival, apoptosis, proliferation, migration, and angiogenic responses. In the mouse, this axis is implicated in immune cell–stromal interactions and injury responses, and it is frequently studied in contexts of chronic inflammation, fibrosis, neuroinflammation, and tumor microenvironment remodeling. Because TWEAK integrates cytokine signaling with repair processes, it is a useful node for dissecting crosstalk between inflammatory mediators and extracellular matrix dynamics.
TWEAK CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Tnfsf12 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Tnfsf12 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Tnfsf12 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TWEAK protein expression.
This CRISPR knockout system enables efficient generation of Tnfsf12-deficient cell models for investigation of TWEAK signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.